Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice

Endocrinology

Volumn 146, Issue 7, 2005, Pages 2952-2962

  Cristina, C ^a,b   Diaz Torga G ^a,b   Baldi, A ^a,b   Gongora A ^a   Rubinstein, M ^a,c,d   Low, M J ^e   Becu Villalobos D ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^c INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; CELL NUCLEUS ANTIGEN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ESTROGEN; HALOPERIDOL; MESSENGER RNA; PROLACTIN; TETRAZOLIUM; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; VASCULOTROPIN A; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; HALOPERIDOL DECANOATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HYPERPLASIA; HYPOPHYSIS CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STELLATE CELL; UMBILICAL VEIN; WILD TYPE; ANIMAL; BLOOD; CELL CULTURE; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; GENETICS; HUMAN; HYPOPHYSIS; METABOLISM; MOUSE MUTANT; PATHOLOGY; TISSUE DISTRIBUTION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOPAMINE ANTAGONISTS; ESTROGENS; FEMALE; HALOPERIDOL; HUMANS; HYPERPLASIA; MICE; MICE, KNOCKOUT; PITUITARY GLAND; PROLACTIN; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TISSUE DISTRIBUTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 22144499643     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1445     Document Type: Article

References (49)

1. Ben-Jonathan N, Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763
2. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG 1998 Dopamine receptors: from structure to function. Physiol Rev 78:189-225
3. Asa SL, Kelly MA, Grandy DK, Low MJ 1999 Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptordeficient mice. Endocrinology 140:5348-5355
4. Hentges ST, Low MJ 2002 Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice. Endocrinology 143:4536-4543
5. Elias KA, Weiner RI 1984 Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549-4553
6. Elias KA, Weiner RI 1987 Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. Endocrinology 120:617-621
7. TakechiA1994 Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol Med Chir (Tokyo) 34:729-733
8. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ 1997 Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113
9. Ferrara N, Gerber H, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676
10. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844
11. Saleh M, Stacker SA, Wilks AF 1996 Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401
12. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229-235
13. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJL 2002 Vascular endothelial endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
14. Banerjee SK, Sarkar DK, Weston AP, De A, Campbell DR 1997 Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogeninitiated tumor angiogenesis. Carcinogenesis 18:1155-1161
15. Cracchiolo D, Swick JW, McKiernan L, Sloan E, Raina S, Sloan C, Wendell DL 2002 Estrogen-dependent growth of a rat pituitary tumor involves, but does not require, a high level of vascular endothelial growth factor. Exp Biol Med (Maywood) 227:492-499
16. Ferrara N, Henzel W 1989 Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858
17. Garrido C, Saule S, Gospodarowicz D 1993 Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors 8:109-117
18. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP 1996 Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci 37:2165-2176
19. Moody TW, Leyton J, Casibang M, Pisegna J, Jensen RT 2002 PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul Pept 109:135-140
20. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D 2001 The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor. Nat Med 7:569-574
21. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ 2002 Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 16:1465-1467
22. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S 2004 Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349-4356
23. Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, Rubinstein M, Becu-Villalobos D 2002 Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology 143:1270-1279
24. Gonzalez Iglesias A, Diaz-Torga G, Piroli G, Achaval-Zaia R, De Nicola AF, Libertun C, Becu-Villalobos D 2000 Bromocriptine restores angiotensin II response in pituitary hyperplasia. Mol Cell Endocrinol 165:67-74
25. Anthony FW, Evans PW, Wheeler T, Wood PJ 1997 Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 34(Pt 3):276-280
26. Shima DT, Kuroki M, Deutsch U, Ng Y, Adamis AP, D'Amore PA 1996 The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 271:3877-3883
27. Jaffe EA, Nachman RL, Becker CG, Minick CR 1973 Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745-2756
28. Onofri C, Carbia NA, Schaaf L, Feirer M, Lohrer P, Stummer W, Berner S, Chervin A, Goldberg V, Stalla GK, Renner U, Arzt E 2004 Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Exp Clin Endocrinol Diabetes 112:18-23
29. Ochoa AL, Mitchner NA, Paynter CD, Morris RE, Ben Jonathan N 2000 Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. J Endocrinol 165:483-492
30. Judd AM, Login IS, Kovacs K, Ross PC, Spangelo BL, Jarvis WD, MacLeod RM1988 Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology 123:2341-2350
31. Vidal S, Kovacs K, Cohen SM, Stefaneanu L, Lloyd RV, ScheithauerBW1999 Localization of vascular endothelial growth factor in non-tumorous human pituitaries. Endocr Pathol 10:109-122
32. Lloyd RV, Vidal S, Horvath E, Kovacs K, Scheithauer B 2003 Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 60:244-250
33. Gospodarowicz D, Abraham JA, Schilling J 1989 Isolation and characterization of a vascular endothelial mitogen produced by pituitary-derived folliculostellate cells. Proc Natl Acad Sci USA 86:7311-7315
34. Jabbour HN, Boddy SC, Lincoln GA 1997 Pattern and localisation of expression of vascular endothelial growth factor and its receptor flt-1 in the ovine pituitary gland: expression is independent of hypothalamic control. Mol Cell Endocrinol 134:91-100
35. Fan L, Iseki S 1998 Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 61:17-28
36. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, Stalla GK, Renner U2001 Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74:95-105
37. Gloddek J, Pagotto U, Paez PM, Arzt E, Stalla GK, Renner U 1999 Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 160:483-490
38. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, Asa SL, Low MJ 2002 Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 110:973-981
39. Joseph F, Younis N, Haydon G, Adams DH, Wynne S, Gillet MB, Maurice YM, Lipton ME, Berstock D, Jones IR 2004 Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor. Eur J Gastroenterol Hepatol 16:1401-1406
40. Park YN, Kim YB, Yang KM, Park C 2000 Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061-1065
41. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD, Chin L 2001 Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 98:7481-7486
42. Yu R, Ren S-G, Horwitz GA, Wang Z, Melmed S 2000 Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 14:1137-1146
43. Vidal S, Lloyd RV, Moya L, Scheithauer BW, Kovacs K 2002 Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary. J Histochem Cytochem 50:533-540
44. Freeman ME, Kanyicska B, Lerant A, Nagy G 2000 Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523-1631
45. Sinha YN, Gilligan TA 1982 Estrogen in high doses inhibits perphenazineinduced prolactin release. Endocrinology 110:126-130
46. Shida N, Ikeda H, Yoshimoto T, Oshima M, Taketo MM, Miyoshi I 1998 Estrogen-induced tumorigenesis in the pituitary gland of TGF-β(+/-) knockout mice. Biochim Biophys Acta 1407:79-83
47. Denef C 2003 Paracrine control of lactotrope proliferation and differentiation. Trends Endocrinol Metab 14:188-195
48. Claffey KP, Wilkison WO, SpiegelmanBM1992 Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 267:16317-16322
49. Sabath DE, Broome HE, Prystowsky MB 1990 Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 91:185-191